Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Epilepsy Treatment Drugs Market

Epilepsy Treatment Drugs Market Share

Report ID: GMI7730
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Epilepsy Treatment Drugs Market Share

The market for epilepsy treatment drugs figures a several key players engaged in competition, utilizing their research expertise and global reach. Competitive strategies involve collaborations, substantial investments in R&D, and a concentration on clinical studies. This market is dynamic, showcasing continual progress, regulatory supports, and activities to meet unmet need in the range of epilepsy treatment.

Epilepsy Treatment Drugs Market Companies

Prominent players operating in the epilepsy treatment drugs industry are as mentioned below:

UCB Pharma S.A.
GlaxoSmithKline Plc
Sanofi
SK Biopharmaceuticals
Eisai Co., Ltd.
Novartis AG
Novel Laboratories Inc.
Pfizer Inc.
Neurelis, Inc.
Bausch Health Companies Inc.
Dr. Reddy's Laboratories
SUMITOMO PHARMA
Jazz Pharmaceuticals, Inc.
Sun Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global epilepsy treatment drugs industry was valued at USD 8.3 billion in 2023 and is expected to reach USD 12.3 billion by 2032 due to the surge in recent approvals for new medications and the escalating prevalence of epilepsy globally.

The adult segment is expected to generate a revenue of USD 8.8 billion by 2032 owing to the higher incidence of epilepsy in adults compared to other age brackets.

North America epilepsy treatment drugs market is anticipated to record 4.3% CAGR from 2023 to 2032 driven by the increasing burden of epilepsy, strategic initiatives by the drug manufacturers, awareness campaigns, and new product launches.

UCB Pharma S.A., GlaxoSmithKline Plc, Sanofi, SK Biopharmaceuticals, Eisai Co., Ltd., Novartis AG, Novel Laboratories Inc., Pfizer Inc., Neurelis, Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories, SUMITOMO PHARMA, Jazz Pharmaceuticals, Inc., and Sun Pharmaceutical Industries Ltd.